

Carragelose®




The universal blocker

Carragelose is iota-carrageenan, a polymer derived from red seaweed that forms a protective layer on mucosal surfaces, enabling a multitude of possible applications:

Viral respiratory diseases

- Unspecifically blocks respiratory viruses causing the common cold
- Clinically validated
- Portfolio of nine marketed nasal and throat products



Eye care

- Moisturizing eye drops
- Relief of dry eyes
- Virus-blocking properties: promising candidate for targeting adenoviral keratoconjunctivitis




Allergy

- Blocks allergens on the mucosal surface
- Effective reduction of allergic symptoms in the nose
- Decongestant effect in combination with sorbitol




Mode of Action

Carragelose forms a protective layer on mucosal surfaces that prevents viruses and allergens from interacting with the mucosal surface. Furthermore, it adds a moisturizing film that helps to keep the mucosa in the nasal cavity and in the throat resilient and as ophthalmic formulation, provides relief of dry eyes.



Without Carragelose:
Virus enters mucosal cell

Carragelose®
→












With Carragelose:
Barrier prevents internalization of virus

Benefits

- Clinically validated and patent protected
- Favourable safety profile - also to be used in children older than one year
- Unspecific blocker against various external influences, such as viruses or allergens
- Full-season and versatile product portfolio
- Carragelose products are classified as medical devices and are on track for MDR transition

Carragelose product portfolio

Product	Launch	Active Ingredients	Claims
 Nasal spray for adults and children 1y+	2008	1.2 mg/ml Carragelose	
 Nasal spray for children 1y+	2012	1.2 mg/ml Carragelose	Prophylactic and supportive treatment of viral infections of the respiratory tract
 Nasal spray for adults and children 1y+	2013	1.2 mg/ml Carragelose + 0.4 mg/ml Kappa-Carrageenan	
 Lozenges for adults and children 6y+	2015	10 mg Carragelose/Lozenge	Prophylactic and supportive treatment of viral infections of the respiratory tract & moistening of the mouth and throat
 Throat spray for adults and children 1y+	2016	1.2 mg/ml Carragelose	
 Nasal spray for adults and children 1y+	2018	1.2 mg/ml Carragelose + 0.4 mg/ml Kappa-Carrageenan + 7% Sorbitol	Prophylactic and supportive treatment of viral infections of the respiratory tract; decongestant effect; anti-allergic
 Nasal and throat spray for adults and children 1y+	2021	1.2 mg/ml Carragelose	Prophylactic treatment of viral respiratory infections
 Nasal spray for adults and children 1y+	2024*	1.2 mg/ml Carragelose	Forms a protective layer on the nasal mucosa that acts as physical barrier against allergens
 Eye drops	2024*	3.2 mg/ml Carragelose	Lubricating and protective

*Anticipated launch

Partnering opportunities

- Anti-allergy nasal spray: Global or territorial license available
- Ophthalmic application: Global or territorial license available
- Virus-blocking portfolio: selected products / countries available
- Private label possible
- Long term partnership requested

About Marinomed Biotech AG

Marinomed Biotech AG is an Austrian, science-based biotech company with globally marketed therapeutics and a growing development pipeline. The Company focuses on the development of innovative products based on two patent-protected technology platforms, Marinolv[®] and Carragelose[®]. Marinomed is listed on the prime market segment of the Vienna Stock Exchange (VSE: MARI).



For more information, please contact our Business Development team:
 E-Mail: bd@marinomed.com
 Tel: +43 2262 90300
www.carragelose.com

Follow us on

[@Marinomed Biotech AG](https://www.instagram.com/Marinomed_Biotech_AG)



[@Marinomed_AG](https://www.twitter.com/Marinomed_AG)



Carragelose[®]

Marinomed Biotech AG, www.marinomed.com
 Hovengasse 25, 2100 Korneuburg, Austria